Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

2Total
P 1 (1)
P 2 (1)

Trial Status

Recruiting2
Enrolling By Invitation1

Clinical Trials (3)

Showing 3 of 3 trials
NCT04930887Phase 2Recruiting

Clinical Trial of Endoscopically Guided Injection of Exparel (Bupivacaine) for the Treatment of Craniofacial Pain

NCT02910323Recruiting

The Will Erwin Headache Research Center - Cluster Headache Study

NCT03511846Phase 1Enrolling By Invitation

Pain Biomarker Study

Showing all 3 trials

Research Network

Activity Timeline